CLINICAL TRIALS PROFILE FOR OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

All Clinical Trials for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00311155 ↗	Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension	Completed	Sankyo Pharma Gmbh	Phase 4	2006-03-01	This study is to assess the safety and efficacy of an add-on treatment algorithm with olmesartan, hydrochlorothiazide and amlodipine in patients with mild to moderate hypertension.
NCT00649389 ↗	Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension	Completed	Daiichi Sankyo Inc.	Phase 3	2008-05-01	To determine the effectiveness of four different strength combinations of three approved anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for lowering blood pressure.
NCT00649389 ↗	Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension	Completed	Daiichi Sankyo, Inc.	Phase 3	2008-05-01	To determine the effectiveness of four different strength combinations of three approved anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for lowering blood pressure.
NCT00791258 ↗	A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure	Completed	Integrium	Phase 4	2008-11-01	The initial 12 week portion of this 20 week study will examine the ability of a combination of olmesartan medoxomil and amlodipine to lower the blood pressure of patients with high blood pressure who have not had sufficient blood pressure reduction using one anti-hypertension drug (monotherapy). The final 8 weeks of this 20 week study will examine the ability of a combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide to lower blood pressure in the same patient population. All three medications being tested have been approved by the FDA for the treatment of high blood pressure, but only amlodipine and olmesartan are currently approved for use in combination form.
NCT00791258 ↗	A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure	Completed	Daiichi Sankyo Inc.	Phase 4	2008-11-01	The initial 12 week portion of this 20 week study will examine the ability of a combination of olmesartan medoxomil and amlodipine to lower the blood pressure of patients with high blood pressure who have not had sufficient blood pressure reduction using one anti-hypertension drug (monotherapy). The final 8 weeks of this 20 week study will examine the ability of a combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide to lower blood pressure in the same patient population. All three medications being tested have been approved by the FDA for the treatment of high blood pressure, but only amlodipine and olmesartan are currently approved for use in combination form.
NCT00791258 ↗	A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure	Completed	Daiichi Sankyo, Inc.	Phase 4	2008-11-01	The initial 12 week portion of this 20 week study will examine the ability of a combination of olmesartan medoxomil and amlodipine to lower the blood pressure of patients with high blood pressure who have not had sufficient blood pressure reduction using one anti-hypertension drug (monotherapy). The final 8 weeks of this 20 week study will examine the ability of a combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide to lower blood pressure in the same patient population. All three medications being tested have been approved by the FDA for the treatment of high blood pressure, but only amlodipine and olmesartan are currently approved for use in combination form.

Clinical Trial Conditions for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

Condition Name

Condition Name for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Intervention	Trials
Essential Hypertension	4
Healthy Subjects	2
Hypertension	2

Condition MeSH

Condition MeSH for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Intervention	Trials
Hypertension	6
Essential Hypertension	4

Clinical Trial Locations for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

Trials by Country

Trials by Country for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Location	Trials
United States	69
Netherlands	2
Belgium	2
Italy	2
Germany	2

Trials by US State

Trials by US State for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Location	Trials
Connecticut	2
New York	2
Washington	2
Florida	2
Wisconsin	2

Clinical Trial Progress for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

Clinical Trial Phase

Clinical Trial Phase for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	3
Phase 1	2

Clinical Trial Status

Clinical Trial Status for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Clinical Trial Phase	Trials
Completed	8

Clinical Trial Sponsors for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

Sponsor Name

Sponsor Name for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Sponsor	Trials
Daiichi Sankyo Inc.	4
Daiichi Sankyo, Inc.	4
Torrent Pharmaceuticals Limited	2

Sponsor Type

Sponsor Type for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Sponsor	Trials
Industry	14